BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31397492)

  • 1. Insulin-like growth factor binding protein 7 accelerates hepatic steatosis and insulin resistance in non-alcoholic fatty liver disease.
    Yan H; Li T; Wang Y; Li H; Xu J; Lu X
    Clin Exp Pharmacol Physiol; 2019 Dec; 46(12):1101-1110. PubMed ID: 31397492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
    Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
    EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease.
    Xiao Z; Chu Y; Qin W
    Life Sci; 2020 Sep; 256():117997. PubMed ID: 32585242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.
    Fu D; Cui H; Zhang Y
    Cell Physiol Biochem; 2018; 45(6):2187-2198. PubMed ID: 29550812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance.
    Kim HY; Park SY; Lee MH; Rho JH; Oh YJ; Jung HU; Yoo SH; Jeong NY; Lee HJ; Suh S; Seo SY; Cheong J; Jeong JS; Yoo YH
    J Hepatol; 2015 Aug; 63(2):477-85. PubMed ID: 25646886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
    Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Procyanidin B2 ameliorates free fatty acids-induced hepatic steatosis through regulating TFEB-mediated lysosomal pathway and redox state.
    Su H; Li Y; Hu D; Xie L; Ke H; Zheng X; Chen W
    Free Radic Biol Med; 2018 Oct; 126():269-286. PubMed ID: 30142454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triterpenic acids-enriched fraction from Cyclocarya paliurus attenuates insulin resistance and hepatic steatosis via PI3K/Akt/GSK3β pathway.
    Zheng X; Zhao MG; Jiang CH; Sheng XP; Yang HM; Liu Y; Yao XM; Zhang J; Yin ZQ
    Phytomedicine; 2020 Jan; 66():153130. PubMed ID: 31790897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
    Liu X; Chen S; Zhang L
    Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator.
    Zhuge B; Li G
    Biochem Biophys Res Commun; 2017 Dec; 494(3-4):687-692. PubMed ID: 29107687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans.
    Cruces-Sande M; Vila-Bedmar R; Arcones AC; González-Rodríguez Á; Rada P; Gutiérrez-de-Juan V; Vargas-Castrillón J; Iruzubieta P; Sánchez-González C; Formentini L; Crespo J; García-Monzón C; Martínez-Chantar ML; Valverde ÁM; Mayor F; Murga C
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3655-3667. PubMed ID: 30261289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GCN2 deficiency protects against high fat diet induced hepatic steatosis and insulin resistance in mice.
    Liu S; Yuan J; Yue W; Bi Y; Shen X; Gao J; Xu X; Lu Z
    Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3257-3267. PubMed ID: 30006154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depletion of Igfbp7 alleviates zebrafish NAFLD progression through inhibiting hepatic ferroptosis.
    Wang Y; Bo J; Zhao Z; Han Y; Zhang Q; Liu L
    Life Sci; 2023 Nov; 332():122086. PubMed ID: 37714372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target genes associated with lipid and glucose metabolism in non-alcoholic fatty liver disease.
    Li T; Yan H; Geng Y; Shi H; Li H; Wang S; Wang Y; Xu J; Zhao G; Lu X
    Lipids Health Dis; 2019 Dec; 18(1):211. PubMed ID: 31805951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease.
    Tang Y; Bian Z; Zhao L; Liu Y; Liang S; Wang Q; Han X; Peng Y; Chen X; Shen L; Qiu D; Li Z; Ma X
    Clin Exp Immunol; 2011 Nov; 166(2):281-90. PubMed ID: 21985374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone H3K9 demethylase JMJD2B induces hepatic steatosis through upregulation of PPARγ2.
    Kim JH; Jung DY; Nagappan A; Jung MH
    Sci Rep; 2018 Sep; 8(1):13734. PubMed ID: 30214048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).
    Soares e Silva AK; de Oliveira Cipriano Torres D; dos Santos Gomes FO; dos Santos Silva B; Lima Ribeiro E; Costa Oliveira A; dos Santos LA; de Lima Mdo C; Pitta Ida R; Peixoto CA
    PLoS One; 2015; 10(4):e0123787. PubMed ID: 25875942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.